drugset / Trial / NCT00824512

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia

NCT00824512

Phase 2 Completed 22 enrolled Ipsen
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus placebo in patients suffering from Friedreich Ataxia

Timeline

Start
2008-06
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ginkgo Biloba Extract Traditional medicine (herbal / TCM) 120 mg Oral

Indications